Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others), By Application (Neurology, Hematology, Oncology, Immunology, Others), By Region and Competition, 2020-2030F

Market Overview

Global Plasma Fractionation Market was valued at USD 25.78 Billion in 2024 and is expected to reach USD 36.82 Billion by 2030 with a CAGR of 6.32%. This is driven by the increasing demand for plasma-derived therapies used in the treatment of a wide range of chronic and rare diseases. These include hemophilia, primary immunodeficiency disorders, and neurological conditions such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The rise in the global aging population, coupled with a higher prevalence of immune-related and bleeding disorders, has created a consistent demand for plasma-derived products such as immunoglobulins, albumin, and clotting factors.

One of the key growth drivers of the market is the continuous expansion of plasma collection networks, particularly in emerging economies where infrastructure development and government-backed healthcare programs are gaining momentum. Despite the positive growth trajectory, the market faces several challenges. High operational costs, complex regulatory requirements, and lengthy production timelines can hinder scalability and profitability. Moreover, increasing competition from recombinant therapies and other biologic alternatives poses a potential threat to traditional plasma-derived products.

Key Market Drivers

Growth in Healthcare Industry

The steady growth of the global healthcare industry has emerged as a key driver of the plasma fractionation market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most lucrative segments, pharmaceuticals and biotechnology account for nearly USD 850 billion, while medical technology and diagnostics contribute over USD 400 billion. With increasing investments in healthcare infrastructure, technological advancements, and broader access to medical services, the demand for plasma-derived therapies has witnessed a substantial rise. These therapies are critical in the treatment of a wide range of life-threatening conditions, including hemophilia, immunodeficiencies, liver diseases, and trauma-related bleeding disorders conditions that are being diagnosed and managed more effectively as healthcare systems evolve.

By 2026, the total number of hospitals worldwide is expected to reach 215,977. While a decline in hospital numbers is anticipated across most regions during the 2021–2026 period, the global total is projected to grow. This overall increase is primarily driven by expansions in just two regions: the Far East & China, and Africa & the Middle East. As hospitals, specialty clinics, and diagnostic centers expand globally particularly in emerging markets the capacity to perform plasma collection, storage, and fractionation has improved significantly. This has led to a more consistent and scalable supply of plasma-derived products such as immunoglobulins, albumin, and coagulation factors. The rise of outpatient care and specialized treatment centers has further accelerated the administration of these therapies, reflecting a broader trend toward personalized and advanced care delivery.

Surge in Technological Advancements

The surge in technological advancements has become a key driver of growth in the global plasma fractionation market. In 2021, Plasma Technologies LLC, a company specializing in plasma biologics technology, announced that its innovative human plasma fractionation process demonstrated the ability to achieve a yield of highly purified immunoglobulin G (IgG) exceeding 74% of the original IgG content present in donor plasma. This yield represents a substantial improvement over conventional manufacturing methods, which utilize outdated protein separation chemistries and deliver comparatively lower recovery rates. Innovations across various stages of the fractionation process have significantly enhanced the safety, efficiency, and scalability of plasma-derived therapies, thereby expanding the market’s scope and competitiveness.

One of the most transformative developments has been the evolution of separation and purification techniques. Traditional fractionation methods are now being replaced or supplemented by advanced technologies such as nanofiltration, improved chromatographic systems, and continuous flow processes. These innovations allow for higher recovery rates of valuable plasma proteins, greater product purity, and a reduction in processing time. As a result, manufacturers can meet the growing demand for immunoglobulins, albumin, and coagulation factors more effectively.

Download Free Sample Report

Key Market Challenges

Limited Plasma Supply & Donation Infrastructure

One of the most significant challenges facing the global plasma fractionation market is the limited availability of plasma due to constrained donation infrastructure. Plasma is the essential raw material for the production of life-saving therapies such as immunoglobulins, clotting factors, and albumin. However, the supply of plasma remains heavily dependent on voluntary donor participation and the presence of well-regulated collection networks, both of which are unevenly distributed across regions.

In many parts of the world, particularly in low- and middle-income countries, plasma donation rates are low, and collection infrastructure is either underdeveloped or virtually nonexistent. This disparity creates a supply-demand imbalance, where the rising global need for plasma-derived therapies cannot be adequately met by current donation volumes. Additionally, the process of collecting plasma through plasmapheresis is time-intensive and requires specialized equipment and trained personnel, further limiting the scalability of collection centers in resource-constrained settings.

Key Market Trends

Increasing Use of Plasma Fractionation in Autoimmune and Neurological Disorders

Over 57 million liters of plasma are utilized globally each year in the production of life-saving therapies that benefit millions of patients. The worldwide demand for Plasma-Derived Therapies (PDTs) has risen significantly over the past two decades and continues on an upward trajectory. A prominent trend shaping the global plasma fractionation market is the rising use of plasma-derived therapies in the treatment of autoimmune and neurological disorders. As the prevalence of conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, myasthenia gravis, and multiple sclerosis continues to grow, healthcare providers are increasingly turning to plasma-derived immunoglobulins and other fractionated products to manage these complex diseases.

Intravenous immunoglobulin (IVIG), a key product of plasma fractionation, has become a cornerstone therapy for several autoimmune and neurological indications due to its immunomodulatory effects. Its widespread clinical acceptance and inclusion in treatment guidelines have significantly contributed to rising demand. In particular, the expansion of clinical applications beyond traditional uses such as in refractory cases or for disease relapse prevention has further bolstered its role in neurological care.

Segmental Insights

Product Insights

Based on Product, Albumin have emerged as the fastest growing segment in the Global Plasma Fractionation Market in 2024. This is due to its expanding clinical applications, increasing demand in emerging economies, and advancements in production technologies. This surge is underpinned by albumin's vital role in treating a broad range of medical conditions, along with its rising use in non-therapeutic sectors. Clinically, albumin is widely used in the management of hypovolemia, burns, shock, trauma, and liver cirrhosis. Its ability to maintain oncotic pressure and facilitate fluid resuscitation makes it a critical therapeutic agent in emergency and critical care settings.

Application Insights

Based on Application, Oncology have emerged as the fastest growing segment in the Global Plasma Fractionation Market during the forecast period. This is due to the increasing use of plasma-derived therapies in managing cancer-related complications and treatment-induced conditions. Cancer patients often experience compromised immune systems, thrombocytopenia, or coagulopathies either as a direct result of the disease or as side effects of chemotherapy and radiation. In such cases, plasma-derived products like immunoglobulins, albumin, and clotting factors play a critical role in supportive care.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Plasma Fractionation Market in 2024. This is due to its advanced healthcare infrastructure, high volume of plasma collection, and strong presence of leading market players. The region, particularly the United States, operates one of the most extensive networks of plasma donation centers, accounting for a significant share of global plasma supply. This robust collection system supports large-scale fractionation operations and ensures a steady flow of raw material for therapeutic production.

Recent Development

• In May 2025, BioRewards Plasma Services, an advanced plasma collection company, formally commenced operations with strategic backing from Alpha-1 Plasma Holdings (“Alpha-1”), a leading investor in plasma collection infrastructure. Supported by a combination of equity commitments and debt financing, BioRewards plans to invest over USD 100 million to establish more than 20 state-of-the-art plasma collection centers across the United States within the next three years. Additional centers are also being conceptualized in strategically important countries outside the U.S. The company is focused on transforming the donor experience, optimizing operational efficiency through advanced technology, and supplying premium-quality plasma materials to fractionators globally.
• In June 2024, Japanese pharmaceutical company Takeda announced an investment of USD 230 million in a new facility in Los Angeles, California, aimed at expanding its plasma-derived therapy (PDT) manufacturing capabilities. The facility is intended to support the treatment of patients with rare, chronic, and genetic conditions, including immunodeficiencies and bleeding disorders. The project is expected to create 125 new jobs and boost Takeda’s plasma fractionation capacity by up to 2 million liters per year. The fractionation process will involve the deployment of advanced separation technologies, such as centrifuges, filter presses, process and buffer tanks, and fluid handling systems. The Los Angeles facility will feature full automation and incorporate sensor-based in-process control (IPC) systems to enhance operational efficiency and product quality.
• In April 2025, SK Plasma announced the arrival of plasma collected in Indonesia at its Andong facility for use in contract manufacturing organization (CMO) plasma fractionation processes. This shipment forms a critical component of a broader initiative launched in 2023, which seeks to build localized production capabilities and advance self-sufficiency in plasma-derived medicinal products (PDMPs) within Indonesia. Significantly, this marks the first time that plasma sourced from Indonesian citizens has been imported into South Korea, reflecting a strategic effort to ensure a stable and sustainable PDMP supply while strengthening international collaboration in biopharmaceutical manufacturing.
• In January 2025, Vietnam initiated the construction of its first plasma-based biopharmaceutical manufacturing facility in the high-tech park of Thu Duc City, Ho Chi Minh City. This strategic development aims to strengthen the national healthcare infrastructure by reducing reliance on imported pharmaceutical products and promoting self-sufficiency in the production of medicines, vaccines, and biopharmaceuticals. The project is in line with government efforts to bolster domestic pharmaceutical manufacturing capabilities. Covering 82,000 square meters, with a total built-up area of 126,000 square meters, the facility represents an investment of approximately USD 114 million. The integrated complex will house production units for plasma fractionation, vaccines, insulin, anesthetics, and oncology drugs, with a planned annual plasma processing capacity of 600,000 litres.

Key Market Players

• Grifols S.A.
• Octapharma AG
• Intas Pharmaceuticals Ltd
• LFB S.A.
• Takeda Pharmaceutical Company Limited
• CSL Limited
• Biotest AG
• Kedrion S.p.A
• Bio Products Laboratory Ltd.
• Bharat Serums and Vaccines Limited

Report Scope

In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Plasma Fractionation Market, By Product:

o   Albumin

o   Immunoglobulins

o   Coagulation Factors

o   Protease Inhibitors

o   Others

• Plasma Fractionation Market, By Application:

o   Neurology

o   Hematology

o   Oncology

o   Immunology

o   Others

• Plasma Fractionation Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.

Available Customizations:

Global Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Plasma Fractionation Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]